Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative colitis

References

• Saverymuttu S. H., Camilleri M., Rees H., Lavender J. P., Hodgson H. J., Chadwick V. S. Indium 111‐granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111‐granulocyte excretion. Gastroenterology 1986; 90: 1121–8
   PubMed Web of Science ®Google Scholar
• Izzo R. S., Witkon K., Chen A. I., Hadjiyane C., Weinstein M. I., Pellecchia C. Interleukin‐8 and neutrophil markers in colonic mucosa from patients with ulcerative colitis. Am J Gastroenterol 1992; 87: 1447–52
   PubMed Web of Science ®Google Scholar
• Carlson M., Raab Y., Seveus L., Xu S., Hallgren R., Venge P. Human neutrophil lipocalin is a unique marker of neutrophil inflammation in ulcerative colitis and proctitis. Gut 2002; 50: 501–6
   PubMed Web of Science ®Google Scholar
• Peterson C. G. B., Eklund E., Taha Y., Raab Y., Carlson M. A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: Establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am J Gastroenterol 2002; 97: 1755–62
   PubMed Web of Science ®Google Scholar
• Sugi K., Saitoh O., Hirata I., Katsu K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: Comparison with other neutrophil‐derived proteins. Am J Gastroenterol 1996; 91: 927–34
   PubMed Web of Science ®Google Scholar
• Bischoff S. C., Wedemeyer J., Herrmann A., Meier P. N., Trautwein C., Cetin Y., et al. Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease. Histopathology 1996; 28: 1–13
   PubMed Web of Science ®Google Scholar
• Raab Y., Fredens K., Gerdin B., Hällgren R. Eosinophil activation in ulcerative colitis: Studies on mucosal release and localization of eosinophil granule constituents. Dig Dis Sci 1998; 43: 1061–70
   PubMed Web of Science ®Google Scholar
• Levy A. M., Gleich G. J., Sandborn W. J., Tremaine W. J., Steiner B. L., Phillips S. F. Increased eosinophil granule proteins in gut lavage fluid from patients with inflammatory bowel disease. Mayo Clin Proc 1997; 72: 117–23
   PubMed Web of Science ®Google Scholar
• Carlson M., Raab Y., Peterson C., Hällgren R., Venge P. Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion. Am J Gastroenterol 1999; 94: 1876–83
   PubMed Web of Science ®Google Scholar
• Lampinen M., Rönnblom A., Amin K., Kristjansson G., Rorsman F., Sangfelt P., et al. Eosinophil granulocytes are activated during the remission phase of ulcerative colitis. Gut 2005; 54: 1714–20
   PubMed Web of Science ®Google Scholar
• Sarin S. K., Malhotra V., Sen G. S., Karol A., Gaur S. K., Anand B. S. Significance of eosinophil and mast cell counts in rectal mucosa in ulcerative colitis. A prospective controlled study. Dig Dis Sci 1987; 32: 363–7
   PubMed Web of Science ®Google Scholar
• Nishida Y., Murase K., Isomoto H., Furusu H., Mizuta Y., Riddell R. H., et al. Different distribution of mast cells and macrophages in colonic mucosa of patients with collagenous colitis and inflammatory bowel disease. Hepatogastroenterology 2002; 49: 678–82
   PubMedGoogle Scholar
• Lloyd G., Green F. H., Fox H., Mani V., Turnberg L. A. Mast cells and immunoglobulin E in inflammatory bowel disease. Gut 1975; 16: 861–6
   PubMed Web of Science ®Google Scholar
• Raithel M., Winterkamp S., Pacurar A., Ulrich P., Hochberger J., Hahn E. G. Release of mast cell tryptase from human colorectal mucosa in inflammatory bowel disease. Scand J Gastroenterol 2001; 36: 174–9
   PubMed Web of Science ®Google Scholar
• Raithel M., Schneider H. T., Hahn E. G. Effect of substance P on histamine secretion from gut mucosa in inflammatory bowel disease. Scand J Gastroenterol 1999; 34: 496–503
   PubMed Web of Science ®Google Scholar
• Brynskov J., Nielsen O. H., Ahnfelt‐Ronne I., Bendtzen K. Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's disease and ulcerative colitis): A review. Dig Dis Sci 1994; 12: 290–304
   Web of Science ®Google Scholar
• Ligumsky M., Simon P. L., Karmeli F., Rachmilewitz D. Role of interleukin 1 in inflammatory bowel disease – enhanced production during active disease. Gut 1990; 31: 686–9
   PubMed Web of Science ®Google Scholar
• Carty E., De Brabander M., Feakins R. M., Rampton D. S. Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper. Gut 2000; 46: 487–92
   PubMed Web of Science ®Google Scholar
• Saiki T., Mitsuyama K., Toyonaga A., Ishida H., Tanikawa K. Detection of pro‐ and anti‐inflammatory cytokines in stools of patients with inflammatory bowel disease. Scand J Gastroenterol 1998; 33: 616–22
   PubMed Web of Science ®Google Scholar
• Wedrychowicz A., Stopyrowa J., Fyderek K., Miezynski W. Stool interleukin 1beta and interleukin 1 receptor antagonist concentrations in children with active ulcerative colitis and during recovery. Eur J Pediatr 2003; 162: 541–2
   PubMed Web of Science ®Google Scholar
• van Deventer S. J. Tumour necrosis factor and Crohn's disease. Gut 1997; 40: 443–8
   PubMed Web of Science ®Google Scholar
• Costa J. J., Matossian K., Resnick M. B., Beil W. J., Wong D. T. W., Gordon J. R., et al. Human eosinophils can express the cytokines tumor necrosis factor‐α and macrophage inflammatory protein‐1α. J Clin Invest 1993; 91: 2673–84
   PubMed Web of Science ®Google Scholar
• Bischoff S. C., Lorentz A., Schwengberg S., Weier G., Raab R., Manns M. P. Mast cells are an important cellular source of tumour necrosis factor alpha in human intestinal tissue. Gut 1999; 44: 643–52
   PubMed Web of Science ®Google Scholar
• Braegger C. P., Nicholls S., Murch S. H., Stephens S., MacDonald T. T. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339: 89–91
   PubMed Web of Science ®Google Scholar
• Nielsen O. H., Vainer B., Madsen S. M., Seidelin J. B., Heegaard N. H. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol 2000; 95: 359–67
   PubMed Web of Science ®Google Scholar
• Garland C. F., Lilienfeld A. M., Mendeloff A. I., Markowitz J. A., Terrell K. B., Garland F. C. Incidence rates of ulcerative colitis and Crohn's disease in fifteen areas of the United States. Gastroenterology 1981; 81: 1115–24
   PubMed Web of Science ®Google Scholar
• Binder V. A comparison between clinical state, macroscopic and microscopic appearances of rectal mucosa, and cytologic picture of mucosal exudate in ulcerative colitis. Scand J Gastroenterol 1970; 5: 627–32
   PubMed Web of Science ®Google Scholar
• Truelove S. C., Richards W. C. Biopsy studies in ulcerative colitis. Br Med J 1956; 1315–18
   PubMed Web of Science ®Google Scholar
• Lettesjö H., Hansson T., Peterson C., Ung K. A., Ringström G., Abrahamsson H., et al. Detection of inflammatory markers in stools from patients with irritable bowel syndrome and collagenous colitis. Scand J Gastroenterol 2006; 41: 54–9
   PubMed Web of Science ®Google Scholar
• Bitton A., Peppercorn M. A., Antonioli D. A., Niles J. L., Shah S., Bousvaros A., et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001; 120: 13–20
   PubMed Web of Science ®Google Scholar
• Strobel S., Miller H. R., Ferguson A. Human intestinal mucosal mast cells: Evaluation of fixation and staining techniques. J Clin Pathol 1981; 34: 851–8
   PubMed Web of Science ®Google Scholar
• King T., Biddle W., Bhatia P., Moore J., Miner P. B, Jr. Colonic mucosal mast cell distribution at line of demarcation of active ulcerative colitis. Dig Dis Sci 1992; 37: 490–5
   PubMed Web of Science ®Google Scholar
• Mahida Y. R., Lamming C. E., Gallagher A., Hawthorne A. B., Hawkey C. J. 5–Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut 1991; 32: 50–4
   PubMed Web of Science ®Google Scholar
• Korelitz B. I. An indicator of Crohn's disease activity. A need unfulfilled. J Clin Gastroenterol 1986; 8: 220–2
   PubMed Web of Science ®Google Scholar
• Gomes P., du Boulay C., Smith C. L., Holdstock G. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986; 27: 92–5
   PubMed Web of Science ®Google Scholar
• Sangfelt P., Carlson M., Thörn M., Lööf L., Raab Y. Neutrophil and eosinophil granule proteins as markers of response to local prednisolone treatment in distal ulcerative colitis and proctitis. Am J Gastroenterol 2001; 96: 1085–90
   PubMed Web of Science ®Google Scholar
• Ishiguro Y. Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis. J Gastroenterol 1999; 34: 66–74
   PubMed Web of Science ®Google Scholar
• Linskens R. K., Van Bodegraven A. A., Schoorl M., Tuynman H. A., Bartels P. Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis. Dig Dis Sci 2001; 46: 644–8
   PubMed Web of Science ®Google Scholar
• Sands B. From symptom to diagnosis: Clinical distinctions among various forms of intestinal inflammation. Gastroenterology 2004; 126: 1518–32
   PubMed Web of Science ®Google Scholar
• Costa F., Mumolo M. G., Bellini M., Romano M. R., Ceccarelli L., Arpe P., et al. Role of faecal calprotectin as non‐invasive marker of intestinal inflammation. Dig Liver Dis 2003; 35: 642–7
   PubMedGoogle Scholar
• Tibble J. A., Sigthorsson G., Foster R., Forgacs I., Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002; 123: 450–60
   PubMed Web of Science ®Google Scholar